AI and biomarkers join forces to spot sepsis in kids faster

NCT ID NCT05311046

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will test a new AI-powered screening tool that uses biomarker data to help doctors recognize sepsis earlier in children arriving at the emergency room. Over 12,000 participants, including children with suspected sepsis and controls, will be enrolled. The goal is to improve early detection and enable more personalized treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could provide a faster, more accurate way to spot sepsis in children, leading to earlier treatment and better outcomes.

What could go wrong

The trial hasn't started yet, and the tool's performance in real-world ER settings is unproven. It may not work as well across different hospitals or patient groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's National Hospital

    Washington D.C., District of Columbia, 20010, United States

    Contact